Patents Assigned to Merck
  • Alkynyl-tolanes, liquid-crystal mixtures containing them and components for high-frequency technology
    Patent number: 10099975
    Abstract: Compounds of formula I their use in liquid-crystalline media, for example, for the phase shifting of microwaves for tunable phased-array antennae, and their use for high-frequency components, in particular antennae, especially for the gigahertz range.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: October 16, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Christian Jasper, Constanze Brocke, Detlef Pauluth, Volker Reiffenrath, Atsutaka Manabe
  • ARYL ACYLSULFONAMIDES AS BLT1 ANTAGONISTS
    Publication number: 20180291017
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Non-alcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.
    Type: Application
    Filed: November 28, 2016
    Publication date: October 11, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
  • CHIRAL COMPOUNDS
    Publication number: 20180291271
    Abstract: The invention relates to chiral compounds of formula I wherein the parameters have the meaning given in claim 1, to liquid crystal mixtures comprising at least one chiral compound of formula I, to chiral linear or crosslinked liquid crystal polymers obtainable by polymerizing a polymerizable mixture comprising at least one chiral compound of formula I, to the use of chiral compound of formula I and mixtures and polymers obtained thereof in liquid crystal displays, active and passive optical elements, adhesives, synthetic resins with anisotropic mechanical properties, cosmetic and pharmaceutical compositions, diagnostics, liquid crystal pigments, for decorative and security applications, nonlinear optics, optical information storage or as chiral dopants, and to a liquid crystal display comprising a mixture comprising at least one chiral compound of formula I.
    Type: Application
    Filed: September 7, 2016
    Publication date: October 11, 2018
    Applicant: Merck Patent GmbH
    Inventors: Matthias BREMER, Edward PLUMMER, Thomas EICHHORN, Peter SCHREINER, Christian KUEHN
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20180291078
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • IN VITRO PHARMACOKINETIC-PHARMACODYNAMIC DEVICE
    Publication number: 20180291325
    Abstract: The present invention provides an in vitro cell culturing bioreactor device capable of supporting the growth of adherent or non-adherent mammalian cells. The invention also provides methods for monitoring and/or measuring the effects of therapeutic agents on cells, for determining the pharmacokinetic-pharmacodynamic relationship between a drug and a target cell, and for determining an effective dosing regimen for a drug or therapeutic agent.
    Type: Application
    Filed: May 9, 2016
    Publication date: October 11, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Donna M. Carr, Michael K. Wismer, Charles G. Garlisi
  • PROCESS FOR PREPARING THIADIAZOLO-ISOINDOLE-DIONE DERIVATIVES
    Publication number: 20180291036
    Abstract: The invention relates to a novel process for preparing 5H-[1,2,5]thiadiazolo[3,4-f]isoindole-5,7(6H)-dione (“TID”) derivatives, especially for preparing 4,8-diaryl-TID derivatives, to novel intermediates obtained and/or used in this process, to novel TID derivatives prepared by this process, to the use of these TID derivatives as monomers or building blocks for preparing conjugated polymers, and to the use of these TID derivatives or conjugated polymers as organic semiconductors or in organic electronic (OE) devices.
    Type: Application
    Filed: September 30, 2015
    Publication date: October 11, 2018
    Applicant: Merck Patent GmbH
    Inventors: Nicolas BLOUIN, Michal KROMPIEC, Andreas LOHR
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20180291270
    Abstract: A liquid-crystalline media comprising one or more compounds of formula S where the parameters have the meaning defined in claim 1, and one or more compounds of the formula I and one or more compounds of the formula II or one or more compounds of the formula I and one or more compounds of the formula III or one or more compounds of the formula II and one or more compounds of the formula III or one or more compounds of the formula I and one or more compounds of the formula II and one or more compounds of the formula III: in which the parameters have the meaning indicated in claim 1, and to components comprising these media for high-frequency technology, in particular phase shifters and microwave array antennas.
    Type: Application
    Filed: April 27, 2016
    Publication date: October 11, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Atsutaka MANABE, Rocco FORTTE, Dagmar KLASS, Renate SEEGER
  • Factor XIa inhibitors
    Patent number: 10093683
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: October 9, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yeon-Hee Lim, Zhuyan Guo, Amjad Ali, Scott D. Edmondson, Weiguo Liu, Gioconda V. Gallo-Etienne, Heping Wu, Ying-Duo Gao, Andrew W. Stamford, Younong Yu, Nancy J. Kevin, Rajan Anand, Deyou Sha, Santhosh F. Neelamkavil, Zahid Hussain, Puneet Kumar, Remond Moningka, Joseph L. Duffy, Jiayi Xu, Yu Jiang, Anjan Chakrabarti, Hiroki Sone
  • Kit for and method of assembling an applicator for inserting an implant
    Patent number: 10092739
    Abstract: The invention pertains to a kit for assembling a disposable applicator for inserting an implant, in particular a rod-like implant containing an active substance, under the skin of a human or animal, the kit comprising a first component, in turn comprising a main housing part providing a handle for grasping and maneuvering the applicator, a cannula, and a cannula holder mounted in the main housing part, the main housing part having an opening which allows introduction of an implant into the proximal end of the cannula or the cannula holder, and, a second component for closing said opening, in turn comprising a second housing part and a rod attached to or forming an integral whole with the second housing part and mountable inside the cannula or the cannula holder.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: October 9, 2018
    Assignee: MERCK SHARP & DOHME B.V.
    Inventors: Dennis Cornelis Franciscus Beelen, Martin Van Harmelen, Robertus Theodoor Maria Moormann, Maurice Petrus Wilhelmus Tak
  • Cyclic amides as MetAP-2 inhibitors
    Patent number: 10093623
    Abstract: Described are cyclic amide compounds of the formula (I): in which R1, R3, R5, R6, R7, R, X and Y have the meanings as described. The compounds are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumors.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: October 9, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Timo Heinrich, Frank Zenke, Mireille Krier, Manja Friese-Hamim, Jeyaprakashnarayanan Seenisamy
  • Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors
    Publication number: 20180280390
    Abstract: The present invention is directed to substituted pyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: May 2, 2016
    Publication date: October 4, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Dong-Ming Shen, Jonathan E. Wilson, Troy McCracken
  • A PHOTOSENSITIVE COMPOSITION AND COLOR CONVERTING FILM
    Publication number: 20180284613
    Abstract: The present invention relates to a photosensitive composition, and a color conversion film. The present invention further relates to a use of the photosensitive composition in a color conversion film fabrication process, and to a use of the color conversion film in an optical device. The invention further more relates to an optical device comprising the color conversion film and method for preparing the color conversion film and the optical device.
    Type: Application
    Filed: August 30, 2016
    Publication date: October 4, 2018
    Applicants: Merck Patent GmbH, AZ Electronic Materials (Luxembourg) S.A.R.L.
    Inventors: Yuki HIRAYAMA, Tadashi KISHIMOTO, Masayoshi SUZUKI, Daishi YOKOYAMA, Katsuto TANIGUCHI, Toshiaki NONAKA
  • SOLID DISPERSIONS OF COMPOUNDS USING POLYVINYL ALCOHOL AS A CARRIER POLYMER
    Publication number: 20180280302
    Abstract: The present invention refers to a method for producing storage-stable solid dispersions of poorly soluble pharmaceutically active compounds comprising polyvinyl alcohol as carrier matrix. The invention also refers to the prepared compositions and their use.
    Type: Application
    Filed: December 22, 2015
    Publication date: October 4, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Shawn KUCERA, Dieter LUBDA, Dave MILLER, Chris BROUGH
  • Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
    Publication number: 20180282415
    Abstract: The present disclosure describes combination therapies useful for the treatment of cancer. In particular, the invention relates to a combination therapy which comprises a PD-1 axis binding antagonist and an ALK inhibitor for treating cancer.
    Type: Application
    Filed: September 27, 2016
    Publication date: October 4, 2018
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Chia-Yang LIN, Wei Wei Wu PRIOR, Yan QU, Changyu WANG
  • Implant comprising FGF-18
    Patent number: 10086112
    Abstract: The invention relates to the field of pharmaceutical compositions. More particularly it is directed to substance delivery system (or implant), such as scaffolds and membranes, comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring
  • Benzamide imidazopyrazine Btk inhibitors
    Patent number: 10087188
    Abstract: The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 2, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jian Liu, Joseph A. Kozlowski, Abdul-Basit Alhassan, Sobhana Babu Boga, Xiaolei Gao, Deodial Guy Guiadeen, Jyhshing Wang, Wensheng Yu, Jiaqiang Cai, Shilan Liu, Dahai Wang, Hao Wu, Chundao Yang
  • Mesogenic media and liquid crystal display
    Patent number: 10087370
    Abstract: The invention relates to mesogenic media comprising a first component, component A, consisting of bimesogenic compounds selected from the group of compounds of formulae A-I to A-III a second component, component B, consisting of nematogenic compounds, preferably selected from the group of compounds of formulae B-I to B-III and a third component, component C, consisting of one or more chiral molecules, wherein the parameters have the meaning given in claim 1, to the use of mesogenic media in flexoelectric liquid crystal devices and to those devices comprising a liquid crystal medium according to the present invention.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: October 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Rachel Tuffin, Benjamin Snow, Owain Llyr Parri, Simon Siemianowski, Rebecca Proctor, Kevin Adlem
  • Cyclic amine azaheterocyclic carboxamides
    Patent number: 10087166
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 2, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • Process for making beta 3 agonists and intermediates
    Patent number: 10087189
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 2, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Formulation inhibiting effects of low acid environment
    Patent number: 10085991
    Abstract: The present invention is directed to formulations comprising PVP polymer, a dispersion of a compound of Formula I (API), and citric acid, which formulations mitigate the effects of coadministering the compound of Formula I with a proton pump inhibitor compound.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: October 2, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lei Zhu, Yvonne Cegielnik, Qun Lu